GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.

GSK names Luke Miels as next CEO, succeeding Emma Walmsley at a pivotal time as the drugmaker sets ambitious growth targets ...

Europe's health regulator has recommended the approval of GSK's cancer treatment Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy, the ...

NEW DELHI: GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision therapies — Jemperli (dostarlimab) and Zejula (niraparib) — aimed at ...

"Pi Health to provide clinical research services in GSK oncology trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...

Walmsley will step down from the board of directors of GSK at the end of the year, and will step down as CEO on 30th ...

Central Pennsylvania is part of GSK ‘s recent announcement that it is investing $30 billion in R&D and manufacturing in the ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial head Luke Miels on Jan. 1.

GSK plc names new CEO as shares rise 3% and maintains a 4% dividend yield; get key insights on GSK stock's outlook and what ...

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the ...